Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC
Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
0 Comments